1 |
Caglara M, Bozkurta FM, Akcaa CK, et al (2012). Comparison of 800 and 3700MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer. Nuclear Med Communications, 33 268-74.
|
2 |
Carballo M, Quiros RM (2012). To treat or not to treat: the role of adjuvant radioiodine therapy in thyroid cancer patients. J Oncol, 2012, 707156.
|
3 |
Cheng W, Ma C, Fu H, et al (2013). Low- or high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis. J Clin Endocrinol Metab, 98, 1353-60.
DOI
ScienceOn
|
4 |
Cooper DS, Doherty GM, Haugen BR (2009). Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 19, 1167-214.
DOI
ScienceOn
|
5 |
Davies L, Welch HG (2002). Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA, 295, 2164-67.
|
6 |
Doi SAR, Woodhouse NJ (2000). Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer. Clin Endocrinol, 52, 763-73.
|
7 |
Doi SAR, Woodhouse NJ, Thalib L, et al (2007). Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer: a meta-analysis revisited. Clinical Med & Res, 5, 87-90.
DOI
ScienceOn
|
8 |
Edwards BK, Howe HL, Ries LA, et al (2002). Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on US cancer burden. Cancer, 94, 2766-92.
DOI
ScienceOn
|
9 |
Elisei R, Molinaro E, Agate L, et al (2010). Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J Clin Endocrinol Metab, 95, 1516-27.
DOI
|
10 |
Grebe SKG, Hay ID (1997). Follicular cell-derived thyroid carcinomas. In: Arnold A, ed, Endocrine neoplasms. Kluwer Academic Publishers, 91-140.
|
11 |
Hackshaw A, Harmer C, Mallick U, et al (2007). 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrinol Metab, 92, 28-38.
DOI
|
12 |
Hay ID, Thompson GB, Grant CS, et al (2002). Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg, 26, 879-85.
DOI
ScienceOn
|
13 |
Haymart MR, Banerjee M, Stewart AK, et al (2011). Use of radioactive iodine for thyroid cancer. JAMA, 306, 721-28.
DOI
ScienceOn
|
14 |
Iyer NG, Morris LG, Tuttle RM, et al (2011). Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer, 117, 4439-46.
DOI
ScienceOn
|
15 |
Jonklaas J, Cooper DS, Ain BK, et al (2010). Radioiodine therapy in patients with stage 1 differentiated thyroid cancer. Thyroid, 20, 1423-6.
DOI
ScienceOn
|
16 |
Leung SF, Law MW, Ho SK (1992). Efficacy of low-dose iodine-131 ablation of post-operative thyroid remnants: a study of 69 cases. Bri J Radiol, 65, 905-9.
DOI
ScienceOn
|
17 |
Maenpaa HO, Heikkonen J, Vaalavirta L, et al (2008). Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. PLoS ONE, 3, 1885
DOI
ScienceOn
|
18 |
Maxon HR, Thomas SR, Hertzberg VS, et al (1983). Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med, 309, 937-41.
DOI
ScienceOn
|
19 |
Mallick U, Harmer C, Hackshaw A, et al (2012). Iodine or not (IoN) for low-risk differentiated thyroid cancer; the next UK national cancer research network randomized trial following HiLo. Clin Oncol, 24, 159-61.
DOI
ScienceOn
|
20 |
Mallick U, Harmer C, Yap B, et al (2012). Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med, 366, 1674-85.
DOI
ScienceOn
|
21 |
Mazzaferri EL, Kloos RT (2001). Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab, 96, 1447-63.
|
22 |
Mazzaferri EL, Young RL (1981). Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med, 70, 511-8.
DOI
ScienceOn
|
23 |
Pacini F, Cetani F, Miccoli P, et al (1994). Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World J Surg, 18, 600-4.
DOI
ScienceOn
|
24 |
Robbins RJ, Schlumberger MJ (2005). The evolving role of 131I for the treatment of differentiated thyroid carcinoma. J Nucl Med, 46, 28-37.
|
25 |
Rubino C, de Vathaire F, Dottorini ME, et al (2003). Second primary malignancies in thyroid cancer patients. Br J Cancer, 89, 1638-44.
DOI
ScienceOn
|
26 |
Sandeep TC, Strachan MW, Reynolds RM, et al (2006). Second primary cancers in thyroid cancer patients: a multinational record linkage study. J Clin Endocrinol Metab, 91, 1819-25.
DOI
ScienceOn
|
27 |
Seidlin S, Oshry E, Yallow AA (1948). Spontaneous and experimentally induced uptake of radioactive iodine in metastases from thyroid carcinoma. J Clin Endocrinol Metab, 8, 423-25.
DOI
|
28 |
Sawka AM, Thephamongkhol K, Brouwers M, et al (2004). Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab, 89, 3668-76.
DOI
ScienceOn
|
29 |
Schlumberger M, Catargi B, Borget I, et al (2012). Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med, 366, 1663-73.
DOI
ScienceOn
|
30 |
Schvartz C, Bonnetain F, Dabakuyo, et al (2012). Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J Clin Endocrinol Metab, 97, 1526-35.
DOI
ScienceOn
|
31 |
Shen DH, Kloos RT, Mazzaferri EL, Jhian SM (2001). Sodium iodide symporter in health and disease. Thyroid, 11, 415-25.
DOI
ScienceOn
|
32 |
Simpson WJ, Panzarella T, Carruthers JS, et al (1998). Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys, 14, 1063-75.
|
33 |
Solomon BL, Wartofsky L, Burman KD (1996). Current trends in the management of well differentiated papillary thyroid carcinoma. J Clin Endocrinol Metab, 81, 333-9.
|
34 |
Vaisman F, Shaha A, Fish S, et al (2001). Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. Clinical Endocrinology, 75, 112-9.
|
35 |
Brierley J, Tsang R, Panzarella T, et al (2005). Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. Clin Endocrinol, 63, 418-27.
DOI
ScienceOn
|
36 |
Bal CS, Kumar A, Pant GS (2004). Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. J Clin Endocrinol Metab, 89, 1666-73.
DOI
|
37 |
Bal CS, Padhy AK, Jana S, et al (1996). Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer, 77, 2574-80.
DOI
|
38 |
Benua RS, Cicle NR, Sonenberg et al (1962). The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol, 87, 171-82.
|
39 |
Yamashita H, Noguchi S, Murakami N, et al (1997). Extracapsular invasion of lymph node metastasis is an indicator of distant metastasis and poor prognosis in patients with thyroid papillary carcinoma. Cancer, 80, 2268-72.
DOI
|
40 |
Wartofsky L, Sherman SI, Gopal J, et al (1998). Therapeutic controversy: the use of radioactive iodine in patients with papillary and follicular thyroid cancer. J Clin Endocrinol Metab, 83, 4195-203.
DOI
|